에 대한 최신 뉴스 Kronos Bio (NASDAQ:KRON) 주식

KRONOS BIO INC

Kronos Bio

Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.

Deal Dispatch

Commodities

Exclusives

Interview

AMCR

BERY

BMWYY

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

GOOG

GOOGL

KRON

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

새로이 등장한 블록 스타벅스(NASDAQ:SBUX)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 경제적 및 경쟁적 압박에 적응하기 위한 파트너십을 모색하고 있다.

딜 디스패치: 스타벅스 중국 사업 매각 고려, 노스볼트 파산, 다윈 파이낸셜이 광업에 대해 논의

AAUKF

APTV

ATSG

FFIV

PARIS:SGO

ROIC

SLGWF

SLNG

TRIP

새로 등장한 블록 에볼런트 헬스(NYSE:EVH)가 매물로 나온 것으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:TPG), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:KKR)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:ELV)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.

딜 디스패치: 쉘, 유니레버 외에도 매각 뉴스; 어니언이 알렉스 존스의 인포워스 인수 등

Kronos Bio Inc

Krones AG

KRONOS ADVANCED TECHS INC by Kronos Advanced Technologies, Inc.

Kronos Advanced Technologies Inc

Kronos Worldwide Inc

Wells Fargo analyst Elyse Greenspan maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Overweight and lowers the price target from $277 to $271.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on RenaissanceRe Holdings, Lowers Price Target to $271

Wells Fargo analyst Elyse Greenspan maintains Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) with a Equal-Weight and lowers the price target from $370 to $362.

Wells Fargo Maintains Equal-Weight on Everest Group, Lowers Price Target to $362

Wall Street trimmed steep losses in afternoon trading Thursday, following remarks from President Donald Trump, who expressed some optimism about reaching trade <a href="https://www.benzinga.com/topic/china">agreements, particularly with China</a>. 
"Would love to be able to work a deal with China," Trump told reporters at the White House. "I think we will end up working out something good for both nations.&#8221;
Trump raised the tariff on imports from China, America's largest trading partner, to 125% on Wednesday. 
&#8220;I think it&#8217;s going to work out,&#8221; Trump added.
Markets reacted swiftly. By 2:50 p.m. ET: 
<ul>
<li>The S&amp;P 500 — tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — was down 3.2%</li>
<li>The Nasdaq 100 trimmed its decline to over 3.8%</li>
<li>The Russell 2000 was off 3.68%. </li>
<li>The Dow Jones Industrial Average also recovered, paring earlier losses from over 4% midday to 2.34%.</li>
</ul>
At midday, the S&amp;P 500 was down 4.8%, the Nasdaq 100 had plunged 5.4%, and the Russell 2000 had dropped 5.3%, wiping out nearly half of Wednesday's historic gains.
<h3 class="wp-block-heading">10% Baseline</h3>
Trump also attacked past trade policies, blaming NAFTA for the loss of nearly 90,000 factories and six million jobs—losses he claimed could have been avoided if tariffs had been in place earlier.
"We're going to bring them all back," Trump said.
Trump highlighted that the European Union initially planned to retaliate against U.S. tariffs but held back after seeing the U.S.&#8217;s aggressive stance against China. &#8220;They were very smart,&#8221; he said.
He also mentioned flexibility in tariff negotiations, suggesting that each country or company might be treated differently depending on the circumstances. 
&#8220;It&#8217;s possible that I would consider flexibility for countries and companies,&#8221; Trump said. &#8220;10% tariff is a baseline. But deals are all different, every country is different.&#8221;
Trump laid out potential uses for the money raised through tariffs, including paying down national debt, reducing the budget and creating border walls.
<h3 class="wp-block-heading">Market Reactions: Gold Eyes Record Close</h3>
At last check Thursday, <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a> data showed:
<ul>
<li>Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) was down 3.6% </li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) down 7%</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) down 3.73%</li>
<li>Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) down 6%, and </li>
<li>Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) down 3.77%.</li>
</ul>
Yields on 30-year Treasury notes were still 8 basis points higher on the day to 4.82%, yet slightly trimming earlier spike during the session.
Gold, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), traded 2.5% higher to $3,160 per ounce, on track to close at fresh record highs. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 3.9% to below $79,500, erasing nearly all Wednesday&#8217;s gains occurred following the 90-day tariff pause announcement.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns">China&#8217;s Growth Outlook Dims As Trump&#8217;s 125% Tariffs Put Millions Of Jobs At Risk, Goldman Warns</a></li>
</ul>
Image: Shutterstock

Asia

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

$BTC

PLTR

TEAM

TSLA

China Deal Is 'Going To Work Out,' Trump Says As Stocks Bounce From Session Lows

Wells Fargo analyst Elyse Greenspan maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $317 to $320.

Wells Fargo Maintains Overweight on Progressive, Raises Price Target to $320

Wells Fargo analyst Elyse Greenspan maintains Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) with a Equal-Weight and raises the price target from $97 to $105.

ROOT

Wells Fargo Maintains Equal-Weight on Root, Raises Price Target to $105

Ratings for AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $492.64, along with a high estimate of $650.00 and a low estimate of $335.00. This current average has increased by 19.26% from the previous average price target of $413.07. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311660_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of AppLovin among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;James Callahan &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $425.00&#x7C;$575.00 &#x7C; 
&#x7C;Matthew Cost &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $350.00&#x7C;$470.00 &#x7C; 
&#x7C;Alec Brondolo &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $386.00&#x7C;$538.00 &#x7C; 
&#x7C;Rob Sanderson &#x7C;Loop Capital &#x7C;Raises &#x7C;Buy &#x7C; $650.00&#x7C;$450.00 &#x7C; 
&#x7C;Jason Bazinet &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $600.00&#x7C;$460.00 &#x7C; 
&#x7C;Martin Yang &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $560.00&#x7C;$480.00 &#x7C; 
&#x7C;Mike Hickey &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $525.00&#x7C;$375.00 &#x7C; 
&#x7C;Cory Carpenter &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $475.00&#x7C;$325.00 &#x7C; 
&#x7C;James Callahan &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $575.00&#x7C;$400.00 &#x7C; 
&#x7C;John Hodulik &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $630.00&#x7C;$440.00 &#x7C; 
&#x7C;Omar Dessouky &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $580.00&#x7C;$375.00 &#x7C; 
&#x7C;Eric Sheridan &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Neutral &#x7C; $335.00&#x7C;$220.00 &#x7C; 
&#x7C;John Hodulik &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $440.00&#x7C;$315.00 &#x7C; 
&#x7C;Alec Brondolo &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $366.00&#x7C;$360.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AppLovin. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AppLovin compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AppLovin's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AppLovin's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AppLovin analyst ratings.</a>
<h2>Delving into AppLovin's Background</h2>
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max, and gaming studios, which develop mobile games. AppLovin announced in February 2025 its plans to divest from the lower-margin gaming studios to focus exclusively on the ad tech platform. AppLovin's primary tool for future growth is Axon 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
<h3>Key Indicators: AppLovin's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3M period, AppLovin showcased positive performance, achieving a revenue growth rate of 44.01% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 43.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AppLovin's ROE stands out, surpassing industry averages. With an impressive ROE of 59.04%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): AppLovin's ROA stands out, surpassing industry averages. With an impressive ROA of 10.58%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: AppLovin's debt-to-equity ratio surpasses industry norms, standing at 3.26. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

14 Analysts Assess AppLovin: What You Need To Know

Rumors

CYBN

Trading Circulation Newsletter Mention Of CYBN

In the preceding three months, 5 analysts have released ratings for Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $24.4, a high estimate of $27.00, and a low estimate of $22.00. Surpassing the previous average price target of $23.20, the current average has increased by 5.17%.
<img src="https://www.benzinga.com/files/images/story/2025/1744311652_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Hamilton Insurance Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $22.00&#x7C;$23.00 &#x7C; 
&#x7C;Tommy McJoynt &#x7C;Keefe, Bruyette &amp; Woods &#x7C;Raises &#x7C;Outperform &#x7C; $25.00&#x7C;$23.00 &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $23.00&#x7C;$21.00 &#x7C; 
&#x7C;Matthew Carletti &#x7C;Citizens Capital Markets&#x7C;Raises &#x7C;Market Outperform&#x7C; $27.00&#x7C;$25.00 &#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $25.00&#x7C;$24.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Hamilton Insurance Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hamilton Insurance Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Hamilton Insurance Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Hamilton Insurance Group's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hamilton Insurance Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Hamilton Insurance Group Better</h2>
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
<h3>Hamilton Insurance Group: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Hamilton Insurance Group displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 15.12%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Hamilton Insurance Group's net margin is impressive, surpassing industry averages. With a net margin of 5.82%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Hamilton Insurance Group's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.46%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Hamilton Insurance Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.43%, the company showcases efficient use of assets and strong financial health.
Debt Management: Hamilton Insurance Group's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Hamilton Insurance Group Through 5 Analysts

13 analysts have expressed a variety of opinions on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $194.0, along with a high estimate of $230.00 and a low estimate of $150.00. Observing a 6.55% increase, the current average has risen from the previous average price target of $182.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311642_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $217.00&#x7C;$200.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $183.00&#x7C;$175.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $179.00&#x7C;$145.00 &#x7C; 
&#x7C;Gregory Fraser &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$220.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $200.00&#x7C;$190.00 &#x7C; 
&#x7C;Charles Duncan &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $150.00&#x7C;$140.00 &#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $176.00&#x7C;$163.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $178.00&#x7C;$179.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $209.00&#x7C;$200.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $210.00&#x7C;$205.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $170.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Jazz Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 7.53% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 4.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.57% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.51.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JAZZ

Where Jazz Pharmaceuticals Stands With Analysts

Wells Fargo analyst Elyse Greenspan maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Equal-Weight and lowers the price target from $79 to $69.

VOYA

Wells Fargo Maintains Equal-Weight on Voya Financial, Lowers Price Target to $69

Financial giants have made a conspicuous bearish move on Cadence Design Systems. Our analysis of options history for Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) revealed 11 unusual trades.
Delving into the details, we found 36% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $151,100, and 7 were calls, valued at $746,770.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $215.0 to $310.0 for Cadence Design Systems over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Cadence Design Systems's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Cadence Design Systems's substantial trades, within a strike price spectrum from $215.0 to $310.0 over the preceding 30 days.
<h3>Cadence Design Systems 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744311637_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDNS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$14.8</td>
<td>$13.8</td>
<td>$13.8</td>
<td>$260.00</td>
<td>$307.7K</td>
<td align="right">178</td>
<td align="right">226</td>
</tr>
<tr>
<td>CDNS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$17.1</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$280.00</td>
<td>$125.8K</td>
<td align="right">248</td>
<td align="right">198</td>
</tr>
<tr>
<td>CDNS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$19.3</td>
<td>$17.5</td>
<td>$17.5</td>
<td>$280.00</td>
<td>$103.2K</td>
<td align="right">248</td>
<td align="right">123</td>
</tr>
<tr>
<td>CDNS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$17.8</td>
<td>$17.1</td>
<td>$17.8</td>
<td>$280.00</td>
<td>$85.4K</td>
<td align="right">248</td>
<td align="right">63</td>
</tr>
<tr>
<td>CDNS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$10.9</td>
<td>$9.0</td>
<td>$9.3</td>
<td>$270.00</td>
<td>$70.6K</td>
<td align="right">145</td>
<td align="right">87</td>
</tr>
</tbody>
</table>

<h3>About Cadence Design Systems</h3>
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enables system-level analysis and verification solutions.
<h3>Present Market Standing of Cadence Design Systems</h3>
<ul>
<li>Trading volume stands at 1,462,340, with CDNS's price down by -2.94%, positioned at $256.88.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 18 days.</li>
</ul>
<h3>What The Experts Say On Cadence Design Systems</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $200.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Underperform rating on Cadence Design Systems, which currently sits at a price target of $200. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cadence Design Systems options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

CDNS

Behind the Scenes of Cadence Design Systems's Latest Options Trends

During the last three months, 16 analysts shared their evaluations of Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">15</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Prudential Financial, revealing an average target of $121.25, a high estimate of $134.00, and a low estimate of $101.00. Highlighting a 3.31% decrease, the current average has fallen from the previous average price target of $125.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311635_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prudential Financial. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $108.00&#x7C;$118.00 &#x7C; 
&#x7C;Ryan Krueger &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Market Perform &#x7C; $120.00&#x7C;$125.00 &#x7C; 
&#x7C;Brian Meredith &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $122.00&#x7C;$130.00 &#x7C; 
&#x7C;John Barnidge &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $122.00&#x7C;$124.00 &#x7C; 
&#x7C;Jimmy Bhullar &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $126.00&#x7C;$128.00 &#x7C; 
&#x7C;Nigel Dally &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $128.00&#x7C;$136.00 &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $118.00&#x7C;$113.00 &#x7C; 
&#x7C;Ryan Krueger &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Market Perform &#x7C; $125.00&#x7C;$129.00 &#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $134.00&#x7C;$128.00 &#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $128.00&#x7C;$127.00 &#x7C; 
&#x7C;Jack Matten &#x7C;BMO Capital &#x7C;Announces &#x7C;Underperform &#x7C; $101.00&#x7C;- &#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $127.00&#x7C;$129.00 &#x7C; 
&#x7C;Ryan Krueger &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Market Perform &#x7C; $129.00&#x7C;$135.00 &#x7C; 
&#x7C;John Barnidge &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $124.00&#x7C;$127.00 &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $113.00&#x7C;$115.00 &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $115.00&#x7C;$117.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Prudential Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Prudential Financial compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Prudential Financial's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Prudential Financial's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PRU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Prudential Financial analyst ratings.</a>
<h2>All You Need to Know About Prudential Financial</h2>
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset-management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 10% of its earnings and has around $1.3 trillion in assets under management. The US businesses are responsible for about 50% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
<h3>Prudential Financial's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Challenges: Prudential Financial's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -17.24%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Prudential Financial's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Prudential Financial's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Prudential Financial's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.01%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.77, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Prudential Financial: Insights From 16 Analyst Reviews

Investors with a lot of money to spend have taken a bearish stance on Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ANET, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 41 uncommon options trades for Arista Networks.
This isn't normal.
The overall sentiment of these big-money traders is split between 29% bullish and 68%, bearish.
Out of all of the special options we uncovered, 24 are puts, for a total amount of $2,138,381, and 17 are calls, for a total amount of $668,720.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $27.5 to $115.0 for Arista Networks over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Arista Networks's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Arista Networks's substantial trades, within a strike price spectrum from $27.5 to $115.0 over the preceding 30 days.
<h3>Arista Networks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744311632_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$20.6</td>
<td>$20.3</td>
<td>$20.5</td>
<td>$85.00</td>
<td>$412.0K</td>
<td>8</td>
<td align="right">202</td>
</tr>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$19.1</td>
<td>$18.9</td>
<td>$19.1</td>
<td>$80.00</td>
<td>$194.8K</td>
<td>275</td>
<td align="right">142</td>
</tr>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$15.0</td>
<td>$14.5</td>
<td>$15.0</td>
<td>$67.50</td>
<td>$168.0K</td>
<td>28</td>
<td align="right">4</td>
</tr>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$20.8</td>
<td>$20.5</td>
<td>$20.8</td>
<td>$85.00</td>
<td>$147.6K</td>
<td>8</td>
<td align="right">274</td>
</tr>
<tr>
<td>ANET</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.3</td>
<td>$5.2</td>
<td>$5.3</td>
<td>$70.00</td>
<td>$139.3K</td>
<td>9.6K</td>
<td align="right">368</td>
</tr>
</tbody>
</table>

<h3>About Arista Networks</h3>
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
<h3>Current Position of Arista Networks</h3>
<ul>
<li>Currently trading with a volume of 7,897,684, the ANET's price is down by -3.45%, now at $73.38. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 26 days.</li>
</ul>
<h3>What The Experts Say On Arista Networks</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $74.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Arista Networks, targeting a price of $76. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Arista Networks, targeting a price of $73. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Arista Networks options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

ANET

Unpacking the Latest Options Trading Trends in Arista Networks

Advanced Drainage Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) short percent of float has fallen 6.52% since its last report. The company recently reported that it has 2.31 million shares sold short, which is 3.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Advanced Drainage Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744311629_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Advanced Drainage Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Advanced Drainage Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Advanced Drainage Systems's peer group average for short interest as a percentage of float is 4.35%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is Advanced Drainage Systems Gaining or Losing Market Support?

Deep-pocketed investors have adopted a bullish approach towards Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NOC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Northrop Grumman. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 54% leaning bullish and 36% bearish. Among these notable options, 4 are puts, totaling $136,202, and 7 are calls, amounting to $220,240.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $505.0 and $540.0 for Northrop Grumman, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Northrop Grumman's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Northrop Grumman's whale activity within a strike price range from $505.0 to $540.0 in the last 30 days. 
<h3>Northrop Grumman 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744311627_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$48.0</td>
<td>$44.0</td>
<td>$48.0</td>
<td>$540.00</td>
<td>$48.0K</td>
<td align="right">10</td>
<td align="right">10</td>
</tr>
<tr>
<td>NOC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$40.8</td>
<td>$40.7</td>
<td>$40.8</td>
<td>$530.00</td>
<td>$44.8K</td>
<td align="right">3</td>
<td align="right">12</td>
</tr>
<tr>
<td>NOC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$23.5</td>
<td>$23.4</td>
<td>$23.4</td>
<td>$510.00</td>
<td>$35.0K</td>
<td align="right">59</td>
<td align="right">32</td>
</tr>
<tr>
<td>NOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$29.4</td>
<td>$27.6</td>
<td>$28.5</td>
<td>$520.00</td>
<td>$31.3K</td>
<td align="right">220</td>
<td align="right">41</td>
</tr>
<tr>
<td>NOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$30.5</td>
<td>$27.3</td>
<td>$29.0</td>
<td>$520.00</td>
<td>$29.0K</td>
<td align="right">220</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Northrop Grumman</h3>
Northrop Grumman Corp is a diversified company which is aligned in four operating sectors, which also comprise our reportable segments namely Aeronautics Systems, Defense Systems, Mission Systems and Space Systems. The aerospace segment designs and builds military aircraft, including the F-35, Global Hawk drones, and the B-21 bomber. Defense systems develops artillery, missile systems, and missile defense technologies. Mission systems focuses on radar, navigation, and communication systems, while space systems manufactures satellites, sensors, and rocket motors.
In light of the recent options history for Northrop Grumman, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Northrop Grumman</h3>
<ul>
<li>Currently trading with a volume of 568,529, the NOC's price is up by 1.5%, now at $520.01. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 12 days.</li>
</ul>
<h3>Expert Opinions on Northrop Grumman</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $575.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a positive move, an analyst from RBC Capital has upgraded their rating to Outperform and adjusted the price target to $575. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Northrop Grumman options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Northrop Grumman

Discover Financial servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) short percent of float has fallen 6.88% since its last report. The company recently reported that it has 5.04 million shares sold short, which is 2.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Discover Financial servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744311623_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Discover Financial servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Discover Financial servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Discover Financial servs's peer group average for short interest as a percentage of float is 8.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Discover Financial servs's Recent Short Interest

In the preceding three months, 5 analysts have released ratings for YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.8, along with a high estimate of $45.00 and a low estimate of $34.00. A 7.69% drop is evident in the current average compared to the previous average price target of $44.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311623_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of YETI Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $34.00&#x7C;$40.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $40.00&#x7C;$45.00 &#x7C; 
&#x7C;Megan Alexander &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $45.00&#x7C;$48.00 &#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $42.00&#x7C;$44.00 &#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $43.00&#x7C;$44.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to YETI Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of YETI Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for YETI Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of YETI Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/YETI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on YETI Holdings analyst ratings.</a>
<h2>About YETI Holdings</h2>
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
<h3>Key Indicators: YETI Holdings's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: YETI Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 5.15%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: YETI Holdings's net margin is impressive, surpassing industry averages. With a net margin of 9.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): YETI Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.04%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): YETI Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: YETI Holdings's debt-to-equity ratio is below the industry average at 0.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YETI

What 5 Analyst Ratings Have To Say About YETI Holdings

Looking into the current session, Bright Horizons Family Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) shares are trading at $117.66, after a 1.55% decrease. Over the past month, the stock decreased by 4.39%, but over the past year, it actually went up by 8.06%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1744311618_0_0.png" alt="Past Year Chart" />

<h3>A Look at Bright Horizons Family P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Bright Horizons Family has a better P/E ratio of 49.8 than the aggregate P/E ratio of 31.42 of the Diversified Consumer Services industry. Ideally, one might believe that Bright Horizons Family Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744311618_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

BFAM

Price Over Earnings Overview: Bright Horizons Family

Autodesk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NYSE">ADSK</a>) short percent of float has fallen 7.28% since its last report. The company recently reported that it has 2.98 million shares sold short, which is 1.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Autodesk Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744311618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Autodesk has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Autodesk's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Autodesk's peer group average for short interest as a percentage of float is 3.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ADSK

Looking Into Autodesk's Recent Short Interest

10 analysts have expressed a variety of opinions on Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $60.0, a high estimate of $85.00, and a low estimate of $41.00. Observing a 18.23% increase, the current average has risen from the previous average price target of $50.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311613_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Brighthouse Finl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $52.00&#x7C;$59.00 &#x7C; 
&#x7C;Nigel Dally &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $41.00&#x7C;$52.00 &#x7C; 
&#x7C;Wilma Burdis &#x7C;Raymond James &#x7C;Announces &#x7C;Strong Buy &#x7C; $72.00&#x7C;- &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $59.00&#x7C;$41.00 &#x7C; 
&#x7C;Ryan Krueger &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Market Perform &#x7C; $66.00&#x7C;$60.00 &#x7C; 
&#x7C;John Barnidge &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $60.00&#x7C;$52.00 &#x7C; 
&#x7C;Suneet Kamath &#x7C;Jefferies &#x7C;Announces &#x7C;Hold &#x7C; $64.00&#x7C;- &#x7C; 
&#x7C;Ryan Krueger &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Market Perform &#x7C; $60.00&#x7C;$48.00 &#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $85.00&#x7C;$52.00 &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $41.00&#x7C;$42.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Brighthouse Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Brighthouse Finl compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Brighthouse Finl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Brighthouse Finl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BHF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Brighthouse Finl analyst ratings.</a>
<h2>All You Need to Know About Brighthouse Finl</h2>
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
<h3>Key Indicators: Brighthouse Finl's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Brighthouse Finl's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -20.93% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Brighthouse Finl's net margin is impressive, surpassing industry averages. With a net margin of 59.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Brighthouse Finl's ROE stands out, surpassing industry averages. With an impressive ROE of 12.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Brighthouse Finl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.27% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Brighthouse Finl's debt-to-equity ratio stands notably higher than the industry average, reaching 0.64. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Brighthouse Financial, Inc. - Common Stock

Breaking Down Brighthouse Finl: 10 Analysts Share Their Views

Press Releases

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

Health Care

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

General

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Earnings

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Management

Kronos Bio Announces CEO Transition and Reduction in Force

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Adicet Bio

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Agenus

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Avalo Therapeutics

bluebird bio

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Citius Oncology

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

ImmuCell

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

MAIA Biotechnology

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PMV Pharma

Quince Therapeutics

Serina Therapeutics

Sutro Biopharma

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Piper Sandler

HC Wainwright & Co.

Goldman Sachs

Berenberg

Kronos

<h3 class="wp-block-heading">새로이 등장한 블록</h3>
<ul>
<li>스타벅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 <a href="https://www.benzinga.com/news/asset-sales/24/11/42117962/starbucks-eyes-stake-sale-in-china-amid-fierce-competition-and-falling-sales">경제적 및 경쟁적 압박</a>에 적응하기 위한 파트너십을 모색하고 있다.</li>
</ul>
<h3 class="wp-block-heading">파산 블록</h3>
<ul>
<li>스낵 제조업체 하스사이드 푸드 솔루션스(Hearthside Food Solutions)이 파산했다. 사모펀드 소속 회사는 파트너스 그룹 홀딩 AG(Partners Group Holding AG)와 찰스뱅크 캐피털 파트너스(Charlesbank Capital Partners)의 소유 하에 쌓인 19억 달러의 부채를 정리하려고 한다. 두 회사는 하스사이드를 24억 달러 이상에 인수했다. 자산과 부채는 각각 10억 달러에서 100억 달러 사이이다. 작년에는 미국에서 파산한 사모펀드 포트폴리오 회사의 수가 <a href="https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/private-equity-portfolio-companies-on-track-for-most-bankruptcies-since-2020-74886821">2020년의 파산 건수를 초과</a>했다. 2024년이 더 나쁠지는 지켜봐야 한다.</li>
</ul>
<ul>
<li>노스볼트(Northvolt)가 58억 달러의 부채로 파산 신청을 했다. 스웨덴 배터리 제조업체인 노스볼트는 폭스바겐 AG(OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>)와 BMW AG(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMWYY#OTC">BMWYY</a>)에 배터리를 공급하며 작년에 <a href="https://www.benzinga.com/news/23/03/31506581/volkswagen-bmw-battery-supplier-northvolt-eyes-raising-5b-via-debt">부채를 조달하기 위해 은행과 협상</a>했던 기억이 있다. 이제는 미국 챕터 11 파산 보호 신청에 따라 구조조정을 희망하고 있다.</li>
</ul>
참고: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42024210/benzinga-bulls-and-bears-tesla-disney-gold-and-hedge-funds-project-bitcoin-to-hit-100k-150k">벤징가의 불스 및 베어스: 테슬라, 디즈니, 금 &#8211; 그리고 헤지펀드가 비트코인이 10만 달러에서 15만 달러에 이를 것이라고 전망</a>
<h3 class="wp-block-heading">블록에서의 업데이트</h3>
<ul>
<li>구글의 앤트로픽(Anthropic)에 대한 20억 달러 투자 계획이 <a href="https://www.benzinga.com/news/large-cap/23/10/35474706/googles-ai-ambitions-grow-with-major-investment-in-openai-rival-anthropic">블룸버그</a>에 따르면 위험에 처해 있다. 앤트로픽은 제프 베이조스가 지원하는 인공지능(AI) 혁신 기업 오픈AI의 경쟁사입니다. 미국 법무부(DOJ)는 <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">수요일 법원 제출에서</a> 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)의 구글이 온라인 검색 독점을 해체하기 위해 크롬 브라우저를 매각해야 한다고 권고했다. 여기서 끝나지 않는다. 규제 당국은 구글이 소비자가 정보를 검색하는 곳을 제어하는 회사와 어떤 거래도 할 수 없도록 금지해야 한다고 말했다. <a href="https://www.benzinga.com/tech/24/11/42123646/google-anthropic-deal-in-jeopardy-as-us-justice-department-looks-to-snap-online-search-monopoly">이에는 AI 제품도 포함</a>된다.</li>
</ul>
<ul>
<li>리키 윌리엄스(Ricky Williams)의 하이즈맨(Highsman)이 대마초 브랜드 프로즌 필즈(Frozen Fields)와 합병하여 톱 시드(Top Seed Inc)를 형성했다. 이 파트너십은 대마초와 대마 산업 분야를 통합하여 제품을 <a href="https://www.benzinga.com/markets/cannabis/24/11/42097662/ricky-williams-highsman-merges-with-hemp-brand-frozen-fields">향상시키고 공급망을 통제</a>한다.</li>
</ul>
<ul>
<li>메이크마이트립(MakeMyTrip)이 하페이(Happay)를 크레드(CRED)로부터 인수했다. 이 거래는 인도에서 기업 여행 및 경비 관리 솔루션을 강화할 것으로 예상된다. 하페이의 팀은 메이크마이트립과 통합되어 <a href="https://www.benzinga.com/general/travel/24/11/42039458/makemytrip-agrees-to-acquire-happay-bolstering-its-arsenal-for-corporate-travel-solutions">900개 이상의 고객을 지원</a>할 것이다.</li>
</ul>
<ul>
<li>앰코(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>)와 베리 글로벌 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>)가 주식 거래로 합병하기로 합의했으며, 이번 거래은 베리 주식을 주당 <a href="https://www.benzinga.com/news/large-cap/24/11/42069248/amcor-and-berry-seal-the-deal-73-59-per-share-merger-to-forge-packaging-powerhouse">73.59달러로 평가</a>했다.</li>
</ul>
<ul>
<li>일본제철(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NISTF#OTC">NISTF</a>)의 경영진이 펜실베니아로 출장을 가서 US 스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)에 대한 150억 달러 인수 제안을 지지받으려 했다. 이 일본 철강 거인은 워싱턴에서 정치적 저항에 직면하고 있다. 모리 타카히로(Takahiro Mori), 일본제철의 부회장이 인수 찬성을 위해 토요일에 피츠버그에 도착했다. 이 거래는 조 바이든 대통령과 도널드 트럼프 대통령 당선자가 모두 미국 철강회사가 <a href="https://www.benzinga.com/markets/24/11/42056111/nippon-steel-execs-rally-support-in-pennsylvania-amid-pushback-on-us-steel-takeover">미국 소유로 남아있기를 선호</a>한다고 반대에 직면하고 있다.</li>
</ul>
<h3 class="wp-block-heading">블록에서의 메모</h3>
다윈 파이낸셜 컴퍼니(Darwin Financial Company)의 공동 설립자 조슈아 로빈슨(Joshua Robinson)은 INYOAG LLC와의 5,500만 달러 자금 조달 거래를 발표했다. 이 자금은 캘리포니아 이노 카운티에 있는 태양열 발전 광산 개발에 사용될 예정이며, 해당 지역에는 은, 납, 아연, 텅스텐 및 구리 매장량이 확인되어 있다. 로빈슨과의 대화 내용은 다음과 같다:
<h4 class="wp-block-heading">BZ: 다윈 금융과 기초 금속 광산업체 INYOAG 간의 거래 구조는 어떻게 되나요? </h4>
로빈슨: 이번 거래 구조는 5,500만 달러 프로젝트 자금 조달 패키지로, 세 가지 구성 요소로 나누어진다: 황화물 및 산화물 생산에 각각 1,750만 달러 및 1,250만 달러의 6년 만기 채권, 그리고 광산이 월 1,000만 달러의 매출을 달성할 경우에만 발동되는 2,000만 달러의 조건부 주식 투자이다. 우리는 두 생산 트랙에서 총 매출의 17%를 확보하며, 이는 안전한 록박스 방식으로 구조화된다. 이것은 단순한 주식 투자가 아니며, 우리는 추가적인 상승 가능성을 제공하기 위해 특별히 이렇게 설계했다.
<h4 class="wp-block-heading">추가 투자자/합작 투자 파트너를 찾고 있나요? </h4>
네, 우리는 이것을 여러 층의 상승 가능성을 창출하기 위해 고의적으로 구조화했다. 이는 광산 분야에서 꽤 독특한 접근 방식이다. 우리는 생산에서의 단기 현금 흐름과 상당한 확장 가능성을 제공하는 하이브리드 모델을 만들었다. 우리는 이미 기존 광산 업체들로부터 관심을 받고 있지만, 특히 중요한 광물의 전략적 가치를 이해하는 새로운 투자자들을 이 분야에 끌어들이는 것에 대해 기대하고 있다.
<h4 class="wp-block-heading">중요 광물의 외국 공급원에 의존하는 것의 단점은 무엇인가요? </h4>
중국의 최근 움직임은 여기서 긴급성을 강조한다. 중국은 이미 게르마늄과 갈륨에 대한 수출 통제를 시행했고, 최근 안티모니도 목록에 추가했다. 이는 더 이상 이론적인 문제가 아니라, 실제로 발생하고 있다. 우리는 방산 및 기술에 필수적인 이러한 광물에 대해 공급망의 지역적 회복력을 구축해야 한다. 다윈 광산은 단일 자산에서 여러 중요한 광물의 국내 공급원을 구축할 수 있는 독특한 기회를 제공한다. 이는 찾기 어려운 일이다.
<h4 class="wp-block-heading">광산은 태양열로 운영되나요? </h4>
100MW 시설은 광산만을 전력 공급하는 것이 아니라, 우리가 생산하는 광물로 발전소 규모의 에너지 저장 시스템을 개발할 수 있는 충분한 청정 에너지를 생성할 것이다. 이는 우리의 광산 운영이 청정 에너지 배치를 직접 지원하는 선순환을 만든다.
<h4 class="wp-block-heading">2025년 목표는 무엇인가요? </h4>
2025년의 주요 목표는 자금 지원 후 6개월 이내에 황화물 생산을 하루 300톤으로, 9개월 이내에 산화물 생산을 하루 200톤으로 끌어올리는 것이다. 이는 월 1,000만 달러의 매출을 달성하게 되며, 그 후 심화된 광산 개발 프로그램이 발동다.
지난 주의 거래 소식은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%89%98-%EC%9C%A0%EB%8B%88%EB%A0%88%EB%B2%84-%EC%99%B8%EC%97%90%EB%8F%84-%EB%A7%A4%EA%B0%81-%EB%89%B4%EC%8A%A4-%EC%96%B4%EB%8B%88%EC%96%B8%EC%9D%B4/" target="_blank" rel="noopener">여기를 클릭하세요</a>.
지금 읽을 내용: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/ai-%EB%AC%BC%EA%B2%B0%EC%9D%84-%ED%83%80%EA%B3%A0-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84%EA%B0%80-%EB%8B%A4%EC%9A%B0%EC%A1%B4%EC%8A%A4-%EC%82%B0%EC%97%85%ED%8F%89%EA%B7%A0-%EC%A7%80%EC%88%98%EC%97%90/" target="_blank" rel="noopener">엔비디아, AI 붐으로 인텔을 다우존스 산업평균지수에서 교체하여 25년간의 지배를 종료</a></li>
</ul>
이미지: Benzinga
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

<h3 class="wp-block-heading">새로 등장한 블록</h3>
에볼런트 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/evh" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for EVH">EVH</a>)가 <a href="https://www.benzinga.com/m-a/24/08/40529349/evolent-health-explores-sale-garners-inbound-interest-from-private-equity-firms" target="_blank" rel="noopener" data-google-interstitial="false">매물로 나온 것</a>으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/tpg" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TPG">TPG</a>), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/kkr" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for KKR">KKR</a>)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/elv" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ELV">ELV</a>)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.
<div class="sc-grPMMF hjTkfb ticker-box-wrapper">암 치료제 개발에 주력하는 기업인 크로노스 바이오(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/kron" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for KRON">KRON</a>)가 인수나 합병 등 &#8216;전략적 대안&#8217;을 모색하고 있다. 캘리포니아주 샌머테이오에 본사를 둔 크로노스 바이오는 9월 30일 현재 1억 2,490만 달러의 현금 보유고를 보고했다.</div>
<div>
생고뱅(OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/codgf" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CODGF">CODGF</a>) (OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/codyy" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CODYY">CODYY</a>)은 <a href="https://www.bloomberg.com/news/articles/2024-11-13/st-gobain-is-said-to-weigh-2-5-billion-sale-of-auto-glass-unit" target="_blank" rel="noopener">블룸버그</a>에 따르면 최대 25억 유로(26억 달러)에 달하는 자동차 유리 사업부 매각을 고려하고 있다. 이 회사는 광범위한 비즈니스 평가의 일환으로 이러한 전략적 움직임을 고려하고 있는 것으로 알려졌다. 이번 매각은 운영을 간소화하고 핵심 사업 분야에 집중하려는 생고뱅(Saint-Gobain)의 노력과 일치한다.
쉘(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/shel" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SHEL" data-google-interstitial="false">SHEL</a>)은 탄소 상쇄 포트폴리오의 대부분을 <a href="https://www.bloomberg.com/news/articles/2024-11-13/shell-aims-to-sell-majority-stake-in-carbon-offsets-business?srnd=phx-deals" target="_blank" rel="noopener">폐기하려고</a> 한다. 이 회사는 <a href="https://www.bloomberg.com/news/features/2023-08-31/shell-silently-abandoned-its-100-million-a-year-plan-to-offset-co2-emissions" target="_blank" rel="noreferrer noopener">2018</a>년에 수십 개의 프로젝트를 포괄하는 오프셋 포트폴리오를 처음 출시했다.
</div>
유니레버(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>)는 우녹스(Unox) 수프, 코니멕스(Conimex) 조미료 등 일부 네덜란드 식품 브랜드의 판매를 모색하고 있다. 로이터에 따르면 회사는 대신 자사의 가장 큰 &#8216;파워&#8217; 라벨에 집중할 것이라고 한다.
<h3 class="wp-block-heading">파산 블록</h3>
알렉스 존스(Alex Jones)의 미디어 회사인 인포워스(Infowars)가 디 어니언(The Onion)에 인수되었다는 소식이다. 이 거래의 뒷받침은 <a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">샌디 훅(</a><a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">Sandy Hook</a><a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">) 피해자</a> 가족들로, 이들은 존스가 10억 달러 이상의 명예훼손 판결을 지고 있는 상황에서 이 거래를 시가에 상징적 정의라고 찬양했다. 일론 머스크 및 터커 칼슨 등 우파 인사들의 <a href="https://www.benzinga.com/news/23/12/36168941/elon-musks-controversial-move-alex-jones-returns-to-x-after-user-vote" target="_blank" rel="noopener" data-google-interstitial="false">동정을 받아온</a> 존스는 눈에 띄게 괴로워하는 소셜 미디어 영상을 통해 &#8220;민주당&#8221;을 비난하며 인수를 확인했다.
다이아몬드 스포츠 그룹(Diamond Sports Group)의 구조 조정에는 부채를 약 90억 달러에서 2억 달러로 줄이는 것이 포함될 것이라고 <a href="https://www.espn.com/mlb/story/_/id/42388454/diamond-sports-group-emerges-bankruptcy" target="_blank" rel="noopener">ESPN</a>이 보도했다. 구조조정 계획은 다이아몬드가 부채 보유자들로부터 &#8220;거의 만장일치의 지지&#8221;로 분류한 것을 받았다. 현재 1억 달러의 유동성을 보유하고 있는 다이아몬드는 파산 상태에서 벗어나 독립 기업으로 운영될 예정이다. 모회사인 싱클레어(Sinclair)는 2019년에 폭스(Fox)로부터 지역 채널을 106억 달러에 인수하기 위해 80억 달러의 빚을 졌다. 그 빚은 다이아몬드의 파산에 기여했다.
<h3 class="wp-block-heading">블록의 업데이트</h3>
현재 휴마나(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/hum" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HUM" data-google-interstitial="false">HUM</a>)가 적극적으로 매각을 추진하고 있다는 구체적인 징후는 없다. 시그나 그룹(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ci" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CI" data-google-interstitial="false">CI</a>)이 휴마나를 인수한다는 최근 추측이 확실하게 해결되었으며, 시그나는 현재로서는 휴마나와의 <a href="https://www.benzinga.com/general/health-care/24/11/41877573/cigna-not-pursuing-humana-merger-stock-soars" target="_blank" rel="noopener" data-google-interstitial="false">합병을 추진하지 않는다</a>고 명시적으로 밝혔다. 이러한 해명은 새로운 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">공화당 행정부와 의회</a> 하에서 보다 관대한 독점 금지 검토가 이루어질 가능성에 따라 선거 후 소문이 다시 불붙은 후에 나온 것이다.
스피릿 항공(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/save" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SAVE" data-google-interstitial="false">SAVE</a>)는 더 이상 프론티어 항공(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ulcc" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ULCC" data-google-interstitial="false">ULCC</a>)과 거래 협상을 진행하지 않는다. 현재 파산 계획을 확정하기 위해 채권 보유자와 사전 논의가 진행 중이다. 이 항공사는 계속해서 증가하는 손실과 다가오는 부채 만기 문제로 어려움을 겪고 있다. <a href="https://www.benzinga.com/news/earnings/24/11/41932146/spirit-airlines-nears-bankruptcy-creditors-may-approve-equity-cancellation-heres-what-it-means-for-investors-as-shares-fall-with-a-thud" target="_blank" rel="noopener" data-google-interstitial="false">월스트리트 저널</a>에 따르면 파산 신청은 몇 주 안에 이뤄질 것으로 예상된다.
<div class="ticker-wrapper">
<div class="sc-grPMMF hjTkfb ticker-box-wrapper">
메이 파마(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/meip" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for MEIP" data-google-interstitial="false">MEIP</a>)는 계속해서 M&amp;A 기회를 모색하고 있으며 오펜하이머(Oppenheimer &amp; Co., Inc.)를 전담 재무 자문사로 고용하여 프로세스를 지원한다. 2025회계연도 1분기 동안 회사는 인력 감축을 포함한 현금 보존 노력을 시작했으며, 이는 회사의 운영 및 전략 방향이 발전함에 따라 단계적으로 계속될 것이다.
<h3 class="wp-block-heading">블록에서의 메모</h3>
월스트리트는 공화당이 의회를 장악하고 규제를 완화함에 따라 M&amp;A가 급증할 것으로 예상하고 있다. 분석가들은 리나 칸(Lina Khan) 연방거래위원회(FTC) 위원장의 해임으로 인해 독점 금지 조사가 쉬워질 것으로 예상하고 있다. 뱅크 오브 아메리카는 도널드 트럼프 대통령 당선자와 같은 공화당 행정부가 역사적으로 민주당 행정부에 비해 금융 부문 M&amp;A 활동을 50% 이상 육성했다는 점을 강조한다.
뱅크 오브 아메리카는 또한 금리 인하가 발효되고 경제 상황이 안정화됨에 따라 2025년은 M&amp;A에 있어 더 좋은 해가 될 수 있다고 예측한다. 다음은 은행이 수집한 5가지 잠재적 목표 목록이다. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">전체 목록</a>을 보려면 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">여기를 클릭</a>하세요.
<table class="block core-block table" style="height: 336px;" width="895">
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>시가 총액 ($M)</th>
<th>기업 가치 대비 잉여 현금 흐름 (%)</th>
<th>장기 성장 기대치 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>유니버셜 헬스 서비스 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/uhs" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for UHS" data-google-interstitial="false">UHS</a>)</td>
<td>헬스케어</td>
<td>13,932</td>
<td>4.4</td>
<td>25.3</td>
</tr>
<tr>
<td>랄프 로렌 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/rl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for RL" data-google-interstitial="false">RL</a>)</td>
<td>소비재</td>
<td>12,473</td>
<td>5.99</td>
<td>10.5</td>
</tr>
<tr>
<td>파라마운트 글로벌 (NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/para" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for PARA" data-google-interstitial="false">PARA</a>)</td>
<td>통신 서비스</td>
<td>7,250</td>
<td>3.4</td>
<td>46.4</td>
</tr>
<tr>
<td>자빌 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/jbl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for JBL" data-google-interstitial="false">JBL</a>)</td>
<td>기술</td>
<td>14,480</td>
<td>6.39</td>
<td>12.7</td>
</tr>
<tr>
<td>해즈브로 (NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/has" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HAS" data-google-interstitial="false">HAS</a>)</td>
<td>소비재</td>
<td>9,215</td>
<td>3.6</td>
<td>27.5</td>
</tr>
</tbody>
</table>
</div>
</div>
지난주 딜 디스패치를 ​​보려면 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%84%A0%EA%B1%B0-%EC%9D%B4%ED%9B%84-%EA%B5%90%EB%8F%84%EC%86%8C-%ED%9A%8C%EC%82%AC%EB%93%A4%EC%97%90-%EC%B4%88%EC%A0%90-%ED%8A%B8%EB%A6%BD%EC%96%B4/" target="_blank" rel="noopener">여기를 클릭</a>하세요.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Kronos Bio

뉴스

에 대한 최신 뉴스 Kronos Bio (NASDAQ:KRON) 주식

토요일, 11월 23, 2024

일요일, 11월 17, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌